跳至主要内容
临床试验/NCT03718182
NCT03718182Unknown4 期

Can Vitamin D Supplementation in People With Crohn's Disease Improve Symptoms as an Adjunct Therapy? D-CODE Feasibility Randomised Controlled Trial

University Hospital Birmingham NHS Foundation Trust2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年9月17日最近更新:
适应症

试验速览

阶段
4 期
发起方
入组人数
50
试验地点
2
主要终点
Inflammatory Bowel Disease Questionnaire (IBDQ)

研究概览

简要总结

There are around 115,000 people in the United Kingdom suffering with Crohn's Disease (CD). CD can cause inflammation and ulcers to develop anywhere within the gut. Symptoms of the disease include diarrhoea, abdominal pain and nutritional problems including vitamin D deficiency. Around half of people with CD are likely to have vitamin D deficiency. Research has shown that treating vitamin D deficiency in people with CD might help to improve the symptoms of the disease. However, there are no clear guidelines on how to detect or treat vitamin D deficiency in people with CD.

There will be two parts to the planned research involving three hospitals in Birmingham. Part 1 is a vitamin D screening study, where adults will be asked to have a finger-prick blood test to check their vitamin D levels. They will complete short diet and lifestyle questionnaires. Adults found to have vitamin D deficiency in part 1 may be invited to join part 2 of the research. Part 2 is a vitamin D supplementation study where participants will be given a daily vitamin D capsule to take by mouth for 6 months. They will be randomly allocated to 2 different groups with each group receiving a different dose of vitamin D. Participants will have blood tests at the start, after 3 months and after 6 months. They will complete quality of life questionnaires at the start and after 6 months. The last appointment will be a final follow up appointment after 9 months.

This research is important to help determine:

  • Which dose of vitamin D is most effective at treating vitamin D deficiency in people with CD
  • If symptoms of CD improve when vitamin D deficiency is treated.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • VITAMIN D SCREENING STUDY
  • With a confirmed diagnosis of Crohn's Disease (CD)
  • ≥ 18 years of age
  • Have provided written informed consent
  • VITAMIN D SUPPLEMENTATION FEASIBILITY TRIAL
  • With a confirmed diagnosis of CD
  • Identified as having Vitamin D deficiency < 50 nmol/L in the Winter screening study
  • ≥ 18 years of age
  • Already receiving treatment for CD as per National Institute for Health and Care Excellence (NICE) Guidance or those in remission and not currently receiving treatment but who continue to attend hospital out-patient appointments
  • Have provided written informed consent

排除标准

  • VITAMIN D SCREENING STUDY
  • VITAMIN D SUPPLEMENTATION FEASIBILITY
  • Currently receiving vitamin D, fish oil or multi-vitamin supplementation and unwilling to stop this to participate in the feasibility trial
  • Currently receiving:
  • Bisphosphonates
  • Digitalis or other cardiac glycosides
  • Phenytoin
  • Barbituates (e.g. Amylobarbitone, Butobarbitone, Methyl Phenobarbitone, Pentobarbitone, Quinalbarbitone, Amylobarbitone)
  • Actinomycin
  • Imidazole
  • With known hyperparathyroidism
  • With known sarcoidosis
  • With known renal disease or kidney stones
  • With known hypercalcaemia (corrected serum calcium ≥2.60 mmol/L)
  • With known underlying liver disease
  • With known hypersensitivity to vitamin D supplements or any of the trial medication excipients
  • Who are pregnant, breast feeding, trying to conceive or women of child-bearing age who decline to have a pregnancy test where applicable. Women who have had a hysterectomy, bilateral oophorectomy or early menopause will not require a pregnancy test.
  • Individuals who have participated in a trial testing a medicinal product within 6 months preceding screening

结局指标

主要结局

Inflammatory Bowel Disease Questionnaire (IBDQ)

时间窗: 6 months

Disease Related Quality of life patient reported outcome measure

次要结局

  • Euroquol EQ-5D-5L(6 months)

研究者

发起方
University Hospital Birmingham NHS Foundation Trust
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jane Fletcher

Nutrition Nurse Lead

University Hospital Birmingham NHS Foundation Trust

研究点 (2)

Loading locations...

相似试验